

National Radiology Data Registry

NMD Physician Screening Report, January-June 2017

(Facility ID: 100853)



nrdr.acr.org



Breast Cancer Surveillance Consortium



Working together to advance
breast cancer research

The National Mammography Database (NMD) thanks the National Cancer Institute funded Breast Cancer Surveillance Consortium (BCSC) for providing benchmark data for comparison with measures for participating facilities.

Measure Definitions

Measure	Definition
All exams	Number of screening exams performed
Recall rate (ACRAD 5)	Number and percent of screening exams with a BI-RADS assessment category of 0, 3, 4 or 5
Biopsy recommended	Number and percent of screening mammograms with either a BI-RADS assessment category of 4 or 5, or a BIRADS assessment category of 0 associated with category 4 or 5 on a diagnostic mammogram
Positive Predictive Value1 (PPV1)	Number and percent of screening exams with a BI-RADS assessment category of 0, 3, 4 or 5 and a tissue diagnosis of cancer within 12 months
Cancers and Positive Predictive Value2 (PPV2) (ACRad 6)	Number of screening exams and percent of screening exams where a biopsy that was recommended resulted in a tissue diagnosis of cancer within 12 months of screening the exam
Positive Predictive Value3 (PPV3)	Number and percent of screening exams where a biopsy that was performed resulted in a tissue diagnosis of cancer within 12 months of screening the exam
Biopsy performed	Number and percent of screening exams with evidence of a biopsy
Cancers and Cancer Detection Rate (CDR) per 1000 (ACRad 3)	Number of screening mammograms with a BI-RADS assessment category of 0, 4 or 5, total and per 1000, that had a tissue diagnosis of cancer within 12 months
Invasive Cancer Detection Rate (ICDR) per 1000 (ACRad 4)	Number of screening mammograms with a BI-RADS assessment category of 0, 4 or 5, total and per 1000, that had a tissue diagnosis of invasive cancer within 12 months (calculated as Invasive cancer rate * CDR)
Ductal Carcinoma in Situ (DCIS)	Number and percent of cancers that were DCIS
Invasive cancer	Number and percent of cancers that were invasive
Minimal cancer (ACRad 8)	Number and percent of cancers that were DCIS or had a tumor size of 10 mm or less

To learn more about the Qualified Clinical Data Registry (QCDR) option and ACRad measures, please click below
<http://www.acr.org/Quality-Safety/National-Radiology-Data-Registry/Qualified-Clinical-Data-Registry>

Measure Definitions

Measure	Definition
Nodal status - negative (ACRad 7)	Number and percent of exams with nodal status indicated where status was negative
Nodal status - positive	Number and percent of exams with nodal status indicated where status was positive
Tumor stage	Number and percent of tumors by stage, where stage is reported
Tumor size	Number and percent of tumors by size, in mm, where size is reported (Tumor size is set to zero for all DCIS lesions)
Inappropriate use of BI-RADS 3 (PQRS 146)	Number and percent of screening exams with a BI-RADS assessment category of 3

***Section 1: Outcome measures and demographic data for exams
performed during January-December 2016 with follow-up through
June 2017***

(Preliminary data for the facility are available in Section 2)

Abnormal Interpretations and Cancers for Screening Mammography
Physician 1013962497: January-December 2016

		1013962497		Facility 100853		All NMD facilities (N=383)		BCSC benchmark*	
Measure	Value	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)
All exams			1,132		5,489		2,961,914		2,410,932
Recall rate		10.95%	(124/1,132)	9.71%	(533/5,489)	9.73%	(288,290/2,961,914)	10.95%	(263,905/2,410,932)
PPV1		5.65%	(7/124)	5.07%	(27/533)	4.25%	(12,239/288,290)		
Cancers and PPV2		40.00%	(6/15)	29.23%	(19/65)	22.00%	(9,770/44,403)	22.90%	(7,613/33,239)
PPV3		50.00%	(6/12)	36.96%	(17/46)	27.13%	(8,462/31,195)		
Biopsy recommended		1.33%	(15/1,132)	1.18%	(65/5,489)	1.50%	(44,403/2,961,914)	1.38%	(33,239/2,410,932)
Biopsy performed		1.68%	(19/1,132)	1.60%	(88/5,489)	1.54%	(45,699/2,961,914)	0.99%	(23,786/2,410,932)
Cancers and CDR per 1000		6.18	(7/1,132)	4.92	(27/5,489)	4.13	(12,239/2,961,914)	4.18	(10,072/2,410,932)
Invasive cancers and ICDR per 1000		5.30	(6/1,132)	4.19	(23/5,489)	3.16	(9,350/2,961,914)		
DCIS		14.29%	(1/7)	14.81%	(4/27)	24.08%	(2,946/12,234)	23.58%	(2,375/10,072)
Invasive cancer		85.71%	(6/7)	85.19%	(23/27)	76.41%	(9,350/12,237)	76.42%	(7,697/10,072)
Minimal cancer		100.00%	(2/2)	72.73%	(8/11)	73.22%	(4,694/6,411)	52.40%	(4,980/9,504)
Nodal status	Negative	75.00%	(3/4)	90.91%	(10/11)	85.57%	(3,245/3,792)	75.95%	(5,629/7,411)
	Positive	25.00%	(1/4)	9.09%	(1/11)	14.43%	(547/3,792)	24.05%	(1,782/7,411)
Tumor size	1-5mm	0.00%	(0/1)	25.00%	(2/8)	16.03%	(587/3,661)		
	6-10mm	100.00%	(1/1)	37.50%	(3/8)	33.41%	(1,223/3,661)		
	11-15mm	0.00%	(0/1)	12.50%	(1/8)	25.16%	(921/3,661)		
	16-20mm	0.00%	(0/1)	12.50%	(1/8)	10.65%	(390/3,661)		
Tumor size: > 20mm		0.00%	(0/1)	12.50%	(1/8)	14.75%	(540/3,661)		
Tumor stage	0	No Data	(./.)	0.00%	(0/2)	15.93%	(434/2,724)		
	I	No Data	(./.)	100.00%	(2/2)	45.34%	(1,235/2,724)		
	II	No Data	(./.)	0.00%	(0/2)	17.03%	(464/2,724)		
	III	No Data	(./.)	0.00%	(0/2)	3.74%	(102/2,724)		

NCI-funded Breast Cancer Surveillance Consortium(BCSC) data on screening mammograms performed 2002-2006.

*BCSC benchmark data are calculated using screen-detected cancers; NMD data may include some interval cancers.

Facility Report:ID 100853





Page 6

January-June 2017

Abnormal Interpretations and Cancers for Screening Mammography
Physician 1013962497: January-December 2016

		1013962497		Facility 100853		All NMD facilities (N=383)		BCSC benchmark*	
Measure	Value		Rate (Num-Den)		Rate (Num-Den)		Rate (Num-Den)		Rate (Num-Den)
	IV		No Data (./.)		0.00% (0/2)		0.62% (17/2,724)		
Assessment category	3		0.09% (1/1,132)		0.07% (4/5,489)		0.23% (6,765/2,950,945)		

BCSC Benchmarks for Screening Exams
Physician 1013962497: January-December 2016



Abnormal Interpretations and Cancers for Screening Mammography
Physician 1255433280: January-December 2016

		1255433280		Facility 100853		All NMD facilities (N=383)		BCSC benchmark*	
Measure	Value	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)
All exams			1,344		5,489		2,961,914		2,410,932
Recall rate		8.78%	(118/1,344)	9.71%	(533/5,489)	9.73%	(288,290/2,961,914)	10.95%	(263,905/2,410,932)
PPV1		6.78%	(8/118)	5.07%	(27/533)	4.25%	(12,239/288,290)		
Cancers and PPV2		33.33%	(5/15)	29.23%	(19/65)	22.00%	(9,770/44,403)	22.90%	(7,613/33,239)
PPV3		35.71%	(5/14)	36.96%	(17/46)	27.13%	(8,462/31,195)		
Biopsy recommended		1.12%	(15/1,344)	1.18%	(65/5,489)	1.50%	(44,403/2,961,914)	1.38%	(33,239/2,410,932)
Biopsy performed		1.71%	(23/1,344)	1.60%	(88/5,489)	1.54%	(45,699/2,961,914)	0.99%	(23,786/2,410,932)
Cancers and CDR per 1000		5.95	(8/1,344)	4.92	(27/5,489)	4.13	(12,239/2,961,914)	4.18	(10,072/2,410,932)
Invasive cancers and ICDR per 1000		5.95	(8/1,344)	4.19	(23/5,489)	3.16	(9,350/2,961,914)		
DCIS		0.00%	(0/8)	14.81%	(4/27)	24.08%	(2,946/12,234)	23.58%	(2,375/10,072)
Invasive cancer		100.00%	(8/8)	85.19%	(23/27)	76.41%	(9,350/12,237)	76.42%	(7,697/10,072)
Minimal cancer		33.33%	(1/3)	72.73%	(8/11)	73.22%	(4,694/6,411)	52.40%	(4,980/9,504)
Nodal status	Negative	100.00%	(4/4)	90.91%	(10/11)	85.57%	(3,245/3,792)	75.95%	(5,629/7,411)
	Positive	0.00%	(0/4)	9.09%	(1/11)	14.43%	(547/3,792)	24.05%	(1,782/7,411)
Tumor size	1-5mm	0.00%	(0/3)	25.00%	(2/8)	16.03%	(587/3,661)		
	6-10mm	33.33%	(1/3)	37.50%	(3/8)	33.41%	(1,223/3,661)		
	11-15mm	33.33%	(1/3)	12.50%	(1/8)	25.16%	(921/3,661)		
	16-20mm	0.00%	(0/3)	12.50%	(1/8)	10.65%	(390/3,661)		
Tumor size: > 20mm		33.33%	(1/3)	12.50%	(1/8)	14.75%	(540/3,661)		
Tumor stage	0	0.00%	(0/1)	0.00%	(0/2)	15.93%	(434/2,724)		
	I	100.00%	(1/1)	100.00%	(2/2)	45.34%	(1,235/2,724)		
	II	0.00%	(0/1)	0.00%	(0/2)	17.03%	(464/2,724)		
	III	0.00%	(0/1)	0.00%	(0/2)	3.74%	(102/2,724)		

NCI-funded Breast Cancer Surveillance Consortium(BCSC) data on screening mammograms performed 2002-2006.

*BCSC benchmark data are calculated using screen-detected cancers; NMD data may include some interval cancers.

Facility Report:ID 100853





Page 9

January-June 2017

Abnormal Interpretations and Cancers for Screening Mammography
Physician 1255433280: January-December 2016

		1255433280		Facility 100853		All NMD facilities (N=383)		BCSC benchmark*	
Measure	Value		Rate (Num-Den)		Rate (Num-Den)		Rate (Num-Den)		Rate (Num-Den)
	IV		0.00% (0/1)		0.00% (0/2)		0.62% (17/2,724)		
Assessment category	3		0.00% (0/1,344)		0.07% (4/5,489)		0.23% (6,765/2,950,945)		

BCSC Benchmarks for Screening Exams
Physician 1255433280: January-December 2016



Abnormal Interpretations and Cancers for Screening Mammography
Physician 1376568014: January-December 2016

		1376568014		Facility 100853		All NMD facilities (N=383)		BCSC benchmark*	
Measure	Value	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)
All exams			563		5,489		2,961,914		2,410,932
Recall rate		8.70%	(49/563)	9.71%	(533/5,489)	9.73%	(288,290/2,961,914)	10.95%	(263,905/2,410,932)
PPV1		2.04%	(1/49)	5.07%	(27/533)	4.25%	(12,239/288,290)		
Cancers and PPV2		50.00%	(1/2)	29.23%	(19/65)	22.00%	(9,770/44,403)	22.90%	(7,613/33,239)
PPV3		No Data	(./.)	36.96%	(17/46)	27.13%	(8,462/31,195)		
Biopsy recommended		0.36%	(2/563)	1.18%	(65/5,489)	1.50%	(44,403/2,961,914)	1.38%	(33,239/2,410,932)
Biopsy performed		1.07%	(6/563)	1.60%	(88/5,489)	1.54%	(45,699/2,961,914)	0.99%	(23,786/2,410,932)
Cancers and CDR per 1000		1.78	(1/563)	4.92	(27/5,489)	4.13	(12,239/2,961,914)	4.18	(10,072/2,410,932)
Invasive cancers and ICDR per 1000		1.78	(1/563)	4.19	(23/5,489)	3.16	(9,350/2,961,914)		
DCIS		0.00%	(0/1)	14.81%	(4/27)	24.08%	(2,946/12,234)	23.58%	(2,375/10,072)
Invasive cancer		100.00%	(1/1)	85.19%	(23/27)	76.41%	(9,350/12,237)	76.42%	(7,697/10,072)
Minimal cancer		No Data	(./.)	72.73%	(8/11)	73.22%	(4,694/6,411)	52.40%	(4,980/9,504)
Nodal status	Negative	No Data	(./.)	90.91%	(10/11)	85.57%	(3,245/3,792)	75.95%	(5,629/7,411)
	Positive	No Data	(./.)	9.09%	(1/11)	14.43%	(547/3,792)	24.05%	(1,782/7,411)
Tumor size	1-5mm	No Data	(./.)	25.00%	(2/8)	16.03%	(587/3,661)		
	6-10mm	No Data	(./.)	37.50%	(3/8)	33.41%	(1,223/3,661)		
	11-15mm	No Data	(./.)	12.50%	(1/8)	25.16%	(921/3,661)		
	16-20mm	No Data	(./.)	12.50%	(1/8)	10.65%	(390/3,661)		
Tumor size: > 20mm		No Data	(./.)	12.50%	(1/8)	14.75%	(540/3,661)		
Tumor stage	0	No Data	(./.)	0.00%	(0/2)	15.93%	(434/2,724)		
	I	No Data	(./.)	100.00%	(2/2)	45.34%	(1,235/2,724)		
	II	No Data	(./.)	0.00%	(0/2)	17.03%	(464/2,724)		
	III	No Data	(./.)	0.00%	(0/2)	3.74%	(102/2,724)		

NCI-funded Breast Cancer Surveillance Consortium(BCSC) data on screening mammograms performed 2002-2006.

*BCSC benchmark data are calculated using screen-detected cancers; NMD data may include some interval cancers.

Facility Report:ID 100853





Page 12

January-June 2017

***Abnormal Interpretations and Cancers for Screening Mammography
Physician 1376568014: January-December 2016***

		1376568014		Facility 100853		All NMD facilities (N=383)		BCSC benchmark*	
Measure	Value		Rate (Num-Den)		Rate (Num-Den)		Rate (Num-Den)		Rate (Num-Den)
	IV		No Data (./.)		0.00% (0/2)		0.62% (17/2,724)		
Assessment category	3		0.00% (0/563)		0.07% (4/5,489)		0.23% (6,765/2,950,945)		

BCSC Benchmarks for Screening Exams
Physician 1376568014: January-December 2016



Abnormal Interpretations and Cancers for Screening Mammography
Physician 1780697441: January-December 2016

		1780697441		Facility 100853		All NMD facilities (N=383)		BCSC benchmark*	
Measure	Value	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)
All exams			1,369		5,489		2,961,914		2,410,932
Recall rate		11.18%	(153/1,369)	9.71%	(533/5,489)	9.73%	(288,290/2,961,914)	10.95%	(263,905/2,410,932)
PPV1		5.88%	(9/153)	5.07%	(27/533)	4.25%	(12,239/288,290)		
Cancers and PPV2		23.81%	(5/21)	29.23%	(19/65)	22.00%	(9,770/44,403)	22.90%	(7,613/33,239)
PPV3		28.57%	(4/14)	36.96%	(17/46)	27.13%	(8,462/31,195)		
Biopsy recommended		1.53%	(21/1,369)	1.18%	(65/5,489)	1.50%	(44,403/2,961,914)	1.38%	(33,239/2,410,932)
Biopsy performed		1.97%	(27/1,369)	1.60%	(88/5,489)	1.54%	(45,699/2,961,914)	0.99%	(23,786/2,410,932)
Cancers and CDR per 1000		6.57	(9/1,369)	4.92	(27/5,489)	4.13	(12,239/2,961,914)	4.18	(10,072/2,410,932)
Invasive cancers and ICDR per 1000		5.11	(7/1,369)	4.19	(23/5,489)	3.16	(9,350/2,961,914)		
DCIS		22.22%	(2/9)	14.81%	(4/27)	24.08%	(2,946/12,234)	23.58%	(2,375/10,072)
Invasive cancer		77.78%	(7/9)	85.19%	(23/27)	76.41%	(9,350/12,237)	76.42%	(7,697/10,072)
Minimal cancer		80.00%	(4/5)	72.73%	(8/11)	73.22%	(4,694/6,411)	52.40%	(4,980/9,504)
Nodal status	Negative	100.00%	(2/2)	90.91%	(10/11)	85.57%	(3,245/3,792)	75.95%	(5,629/7,411)
	Positive	0.00%	(0/2)	9.09%	(1/11)	14.43%	(547/3,792)	24.05%	(1,782/7,411)
Tumor size	1-5mm	50.00%	(2/4)	25.00%	(2/8)	16.03%	(587/3,661)		
	6-10mm	25.00%	(1/4)	37.50%	(3/8)	33.41%	(1,223/3,661)		
	11-15mm	0.00%	(0/4)	12.50%	(1/8)	25.16%	(921/3,661)		
	16-20mm	25.00%	(1/4)	12.50%	(1/8)	10.65%	(390/3,661)		
Tumor size: > 20mm		0.00%	(0/4)	12.50%	(1/8)	14.75%	(540/3,661)		
Tumor stage	0	0.00%	(0/1)	0.00%	(0/2)	15.93%	(434/2,724)		
	I	100.00%	(1/1)	100.00%	(2/2)	45.34%	(1,235/2,724)		
	II	0.00%	(0/1)	0.00%	(0/2)	17.03%	(464/2,724)		
	III	0.00%	(0/1)	0.00%	(0/2)	3.74%	(102/2,724)		

NCI-funded Breast Cancer Surveillance Consortium(BCSC) data on screening mammograms performed 2002-2006.

*BCSC benchmark data are calculated using screen-detected cancers; NMD data may include some interval cancers.

Facility Report:ID 100853





Page 15

January-June 2017

Abnormal Interpretations and Cancers for Screening Mammography
Physician 1780697441: January-December 2016

		1780697441		Facility 100853		All NMD facilities (N=383)		BCSC benchmark*	
Measure	Value		Rate (Num-Den)		Rate (Num-Den)		Rate (Num-Den)		Rate (Num-Den)
	IV		0.00% (0/1)		0.00% (0/2)		0.62% (17/2,724)		
Assessment category	3		0.15% (2/1,369)		0.07% (4/5,489)		0.23% (6,765/2,950,945)		

BCSC Benchmarks for Screening Exams
Physician 1780697441: January-December 2016



Abnormal Interpretations and Cancers for Screening Mammography
Physician 1780766014: January-December 2016

		1780766014		Facility 100853		All NMD facilities (N=383)		BCSC benchmark*	
Measure	Value	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)
All exams		1,081		5,489		2,961,914		2,410,932	
Recall rate		8.23%	(89/1,081)	9.71%	(533/5,489)	9.73%	(288,290/2,961,914)	10.95%	(263,905/2,410,932)
PPV1		2.25%	(2/89)	5.07%	(27/533)	4.25%	(12,239/288,290)		
Cancers and PPV2		16.67%	(2/12)	29.23%	(19/65)	22.00%	(9,770/44,403)	22.90%	(7,613/33,239)
PPV3		33.33%	(2/6)	36.96%	(17/46)	27.13%	(8,462/31,195)		
Biopsy recommended		1.11%	(12/1,081)	1.18%	(65/5,489)	1.50%	(44,403/2,961,914)	1.38%	(33,239/2,410,932)
Biopsy performed		1.20%	(13/1,081)	1.60%	(88/5,489)	1.54%	(45,699/2,961,914)	0.99%	(23,786/2,410,932)
Cancers and CDR per 1000		1.85	(2/1,081)	4.92	(27/5,489)	4.13	(12,239/2,961,914)	4.18	(10,072/2,410,932)
Invasive cancers and ICDR per 1000		0.93	(1/1,081)	4.19	(23/5,489)	3.16	(9,350/2,961,914)		
DCIS		50.00%	(1/2)	14.81%	(4/27)	24.08%	(2,946/12,234)	23.58%	(2,375/10,072)
Invasive cancer		50.00%	(1/2)	85.19%	(23/27)	76.41%	(9,350/12,237)	76.42%	(7,697/10,072)
Minimal cancer		100.00%	(1/1)	72.73%	(8/11)	73.22%	(4,694/6,411)	52.40%	(4,980/9,504)
Nodal status	Negative	100.00%	(1/1)	90.91%	(10/11)	85.57%	(3,245/3,792)	75.95%	(5,629/7,411)
	Positive	0.00%	(0/1)	9.09%	(1/11)	14.43%	(547/3,792)	24.05%	(1,782/7,411)
Tumor size	1-5mm	No Data	(./.)	25.00%	(2/8)	16.03%	(587/3,661)		
	6-10mm	No Data	(./.)	37.50%	(3/8)	33.41%	(1,223/3,661)		
	11-15mm	No Data	(./.)	12.50%	(1/8)	25.16%	(921/3,661)		
	16-20mm	No Data	(./.)	12.50%	(1/8)	10.65%	(390/3,661)		
Tumor size: > 20mm		No Data	(./.)	12.50%	(1/8)	14.75%	(540/3,661)		
Tumor stage	0	No Data	(./.)	0.00%	(0/2)	15.93%	(434/2,724)		
	I	No Data	(./.)	100.00%	(2/2)	45.34%	(1,235/2,724)		
	II	No Data	(./.)	0.00%	(0/2)	17.03%	(464/2,724)		
	III	No Data	(./.)	0.00%	(0/2)	3.74%	(102/2,724)		

NCI-funded Breast Cancer Surveillance Consortium(BCSC) data on screening mammograms performed 2002-2006.

*BCSC benchmark data are calculated using screen-detected cancers; NMD data may include some interval cancers.

Facility Report:ID 100853





Page 18

January-June 2017


***Abnormal Interpretations and Cancers for Screening Mammography
Physician 1780766014: January-December 2016***

		1780766014		Facility 100853		All NMD facilities (N=383)		BCSC benchmark*	
Measure	Value		Rate (Num-Den)		Rate (Num-Den)		Rate (Num-Den)		Rate (Num-Den)
	IV		No Data (./.)		0.00% (0/2)		0.62% (17/2,724)		
Assessment category	3		0.09% (1/1,081)		0.07% (4/5,489)		0.23% (6,765/2,950,945)		

BCSC Benchmarks for Screening Exams
Physician 1780766014: January-December 2016



***Abnormal Interpretations and Cancers for Screening Mammography
Recall Rate and PPV2
January-December 2016: Physician Comparisons***




**BCSC benchmark data are calculated using screen-detected cancers; NMD data may include some interval cancers.*

Facility Report:ID 100853

Page 21

January-June 2017

***Abnormal Interpretations and Cancers for Screening Mammography
PPV1
January-December 2016: Physician Comparisons***




**BCSC benchmark data are calculated using screen-detected cancers; NMD data may include some interval cancers.*

Facility Report:ID 100853

Page 22

January-June 2017

***Abnormal Interpretations and Cancers for Screening Mammography
PPV3
January-December 2016: Physician Comparisons***




**BCSC benchmark data are calculated using screen-detected cancers; NMD data may include some interval cancers.*

Facility Report:ID 100853

Page 23

January-June 2017

***Abnormal Interpretations and Cancers for Screening Mammography
Cancer Detection Rate (CDR)
January-December 2016: Physician Comparisons***




**BCSC benchmark data are calculated using screen-detected cancers; NMD data may include some interval cancers.*

Facility Report:ID 100853

Page 24

January-June 2017

***Abnormal Interpretations and Cancers for Screening Mammography
Biopsy Results
January-December 2016: Physician Comparisons***



**BCSC benchmark data are calculated using screen-detected cancers; NMD data may include some interval cancers.*

Facility Report:ID 100853

Section 2: Preliminary data on exams performed during June 2017

Preliminary outcome data
Abnormal Interpretations and Cancers for Screening Mammography
Physician 1013962497: January-June 2017

		1013962497		Facility 100853		All NMD facilities (N=359)	
Measure	Value	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)
All exams			634		3,236		1,474,187
Recall rate		11.04%	(70/634)	9.46%	(306/3,236)	9.83%	(144,919/1,474,187)
PPV1		5.71%	(4/70)	6.86%	(21/306)	3.61%	(5,226/144,919)
Cancers and PPV2		42.86%	(3/7)	27.03%	(10/37)	18.94%	(4,071/21,492)
PPV3		50.00%	(3/6)	27.59%	(8/29)	27.33%	(3,526/12,900)
Biopsy recommended		1.10%	(7/634)	1.14%	(37/3,236)	1.46%	(21,492/1,474,187)
Biopsy performed		1.58%	(10/634)	1.64%	(53/3,236)	1.27%	(18,764/1,474,187)
Cancers and CDR per 1000		6.31	(4/634)	6.49	(21/3,236)	3.55	(5,226/1,474,187)
Invasive cancers and ICDR per 1000		4.73	(3/634)	4.33	(14/3,236)	2.70	(3,987/1,474,187)
DCIS		25.00%	(1/4)	33.33%	(7/21)	23.90%	(1,249/5,225)
Invasive cancer		75.00%	(3/4)	66.67%	(14/21)	76.31%	(3,987/5,225)
Minimal cancer		100.00%	(1/1)	68.75%	(11/16)	73.25%	(1,955/2,669)
Nodal status	Negative	100.00%	(2/2)	71.43%	(5/7)	87.54%	(1,180/1,348)
	Positive	0.00%	(0/2)	28.57%	(2/7)	12.46%	(168/1,348)
Tumor size	1-5mm	No Data	(./.)	30.00%	(3/10)	15.12%	(233/1,541)
	6-10mm	No Data	(./.)	10.00%	(1/10)	34.46%	(531/1,541)
	11-15mm	No Data	(./.)	20.00%	(2/10)	26.15%	(403/1,541)
	16-20mm	No Data	(./.)	20.00%	(2/10)	10.25%	(158/1,541)
Tumor size: > 20mm		No Data	(./.)	20.00%	(2/10)	14.02%	(216/1,541)
Tumor stage	0	No Data	(./.)	0.00%	(0/1)	15.34%	(148/965)
	I	No Data	(./.)	0.00%	(0/1)	44.04%	(425/965)
	II	No Data	(./.)	0.00%	(0/1)	8.91%	(86/965)
	III	No Data	(./.)	0.00%	(0/1)	2.80%	(27/965)

***Preliminary outcome data
Abnormal Interpretations and Cancers for Screening Mammography
Physician 1013962497: January-June 2017***

		1013962497		Facility 100853		All NMD facilities (N=359)	
Measure	Value	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)
	IV	No Data	(./.)	0.00%	(0/1)	0.52%	(5/965)
Assessment category	3	0.00%	(0/634)	0.06%	(2/3,236)	0.34%	(4,939/1,474,187)

Preliminary outcome data
Abnormal Interpretations and Cancers for Screening Mammography
Physician 1255433280: January-June 2017

		1255433280		Facility 100853		All NMD facilities (N=359)	
Measure	Value	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)
All exams			811		3,236		1,474,187
Recall rate		9.00%	(73/811)	9.46%	(306/3,236)	9.83%	(144,919/1,474,187)
PPV1		5.48%	(4/73)	6.86%	(21/306)	3.61%	(5,226/144,919)
Cancers and PPV2		10.00%	(1/10)	27.03%	(10/37)	18.94%	(4,071/21,492)
PPV3		12.50%	(1/8)	27.59%	(8/29)	27.33%	(3,526/12,900)
Biopsy recommended		1.23%	(10/811)	1.14%	(37/3,236)	1.46%	(21,492/1,474,187)
Biopsy performed		1.60%	(13/811)	1.64%	(53/3,236)	1.27%	(18,764/1,474,187)
Cancers and CDR per 1000		4.93	(4/811)	6.49	(21/3,236)	3.55	(5,226/1,474,187)
Invasive cancers and ICDR per 1000		1.23	(1/811)	4.33	(14/3,236)	2.70	(3,987/1,474,187)
DCIS		75.00%	(3/4)	33.33%	(7/21)	23.90%	(1,249/5,225)
Invasive cancer		25.00%	(1/4)	66.67%	(14/21)	76.31%	(3,987/5,225)
Minimal cancer		100.00%	(3/3)	68.75%	(11/16)	73.25%	(1,955/2,669)
Nodal status	Negative	No Data	(./.)	71.43%	(5/7)	87.54%	(1,180/1,348)
	Positive	No Data	(./.)	28.57%	(2/7)	12.46%	(168/1,348)
Tumor size	1-5mm	0.00%	(0/1)	30.00%	(3/10)	15.12%	(233/1,541)
	6-10mm	0.00%	(0/1)	10.00%	(1/10)	34.46%	(531/1,541)
	11-15mm	0.00%	(0/1)	20.00%	(2/10)	26.15%	(403/1,541)
	16-20mm	0.00%	(0/1)	20.00%	(2/10)	10.25%	(158/1,541)
Tumor size: > 20mm		100.00%	(1/1)	20.00%	(2/10)	14.02%	(216/1,541)
Tumor stage	0	No Data	(./.)	0.00%	(0/1)	15.34%	(148/965)
	I	No Data	(./.)	0.00%	(0/1)	44.04%	(425/965)
	II	No Data	(./.)	0.00%	(0/1)	8.91%	(86/965)
	III	No Data	(./.)	0.00%	(0/1)	2.80%	(27/965)

***Preliminary outcome data
Abnormal Interpretations and Cancers for Screening Mammography
Physician 1255433280: January-June 2017***

		1255433280		Facility 100853		All NMD facilities (N=359)	
Measure	Value	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)
	IV	No Data	(./.)	0.00%	(0/1)	0.52%	(5/965)
Assessment category	3	0.12%	(1/811)	0.06%	(2/3,236)	0.34%	(4,939/1,474,187)

Preliminary outcome data
Abnormal Interpretations and Cancers for Screening Mammography
Physician 1376568014: January-June 2017

		1376568014		Facility 100853		All NMD facilities (N=359)	
Measure	Value	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)
All exams			304		3,236		1,474,187
Recall rate		11.84%	(36/304)	9.46%	(306/3,236)	9.83%	(144,919/1,474,187)
PPV1		8.33%	(3/36)	6.86%	(21/306)	3.61%	(5,226/144,919)
Cancers and PPV2		50.00%	(2/4)	27.03%	(10/37)	18.94%	(4,071/21,492)
PPV3		33.33%	(1/3)	27.59%	(8/29)	27.33%	(3,526/12,900)
Biopsy recommended		1.32%	(4/304)	1.14%	(37/3,236)	1.46%	(21,492/1,474,187)
Biopsy performed		1.97%	(6/304)	1.64%	(53/3,236)	1.27%	(18,764/1,474,187)
Cancers and CDR per 1000		9.87	(3/304)	6.49	(21/3,236)	3.55	(5,226/1,474,187)
Invasive cancers and ICDR per 1000		6.58	(2/304)	4.33	(14/3,236)	2.70	(3,987/1,474,187)
DCIS		33.33%	(1/3)	33.33%	(7/21)	23.90%	(1,249/5,225)
Invasive cancer		66.67%	(2/3)	66.67%	(14/21)	76.31%	(3,987/5,225)
Minimal cancer		100.00%	(3/3)	68.75%	(11/16)	73.25%	(1,955/2,669)
Nodal status	Negative	100.00%	(1/1)	71.43%	(5/7)	87.54%	(1,180/1,348)
	Positive	0.00%	(0/1)	28.57%	(2/7)	12.46%	(168/1,348)
Tumor size	1-5mm	50.00%	(1/2)	30.00%	(3/10)	15.12%	(233/1,541)
	6-10mm	50.00%	(1/2)	10.00%	(1/10)	34.46%	(531/1,541)
	11-15mm	0.00%	(0/2)	20.00%	(2/10)	26.15%	(403/1,541)
	16-20mm	0.00%	(0/2)	20.00%	(2/10)	10.25%	(158/1,541)
Tumor size: > 20mm		0.00%	(0/2)	20.00%	(2/10)	14.02%	(216/1,541)
Tumor stage	0	No Data	(./.)	0.00%	(0/1)	15.34%	(148/965)
	I	No Data	(./.)	0.00%	(0/1)	44.04%	(425/965)
	II	No Data	(./.)	0.00%	(0/1)	8.91%	(86/965)
	III	No Data	(./.)	0.00%	(0/1)	2.80%	(27/965)

***Preliminary outcome data
Abnormal Interpretations and Cancers for Screening Mammography
Physician 1376568014: January-June 2017***

		1376568014		Facility 100853		All NMD facilities (N=359)	
Measure	Value	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)
	IV	No Data	(./.)	0.00%	(0/1)	0.52%	(5/965)
Assessment category	3	0.00%	(0/304)	0.06%	(2/3,236)	0.34%	(4,939/1,474,187)

Preliminary outcome data
Abnormal Interpretations and Cancers for Screening Mammography
Physician 1780697441: January-June 2017

		1780697441		Facility 100853		All NMD facilities (N=359)	
Measure	Value	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)
All exams			834		3,236		1,474,187
Recall rate		9.83%	(82/834)	9.46%	(306/3,236)	9.83%	(144,919/1,474,187)
PPV1		7.32%	(6/82)	6.86%	(21/306)	3.61%	(5,226/144,919)
Cancers and PPV2		18.18%	(2/11)	27.03%	(10/37)	18.94%	(4,071/21,492)
PPV3		22.22%	(2/9)	27.59%	(8/29)	27.33%	(3,526/12,900)
Biopsy recommended		1.32%	(11/834)	1.14%	(37/3,236)	1.46%	(21,492/1,474,187)
Biopsy performed		1.92%	(16/834)	1.64%	(53/3,236)	1.27%	(18,764/1,474,187)
Cancers and CDR per 1000		7.19	(6/834)	6.49	(21/3,236)	3.55	(5,226/1,474,187)
Invasive cancers and ICDR per 1000		6.00	(5/834)	4.33	(14/3,236)	2.70	(3,987/1,474,187)
DCIS		16.67%	(1/6)	33.33%	(7/21)	23.90%	(1,249/5,225)
Invasive cancer		83.33%	(5/6)	66.67%	(14/21)	76.31%	(3,987/5,225)
Minimal cancer		60.00%	(3/5)	68.75%	(11/16)	73.25%	(1,955/2,669)
Nodal status	Negative	50.00%	(2/4)	71.43%	(5/7)	87.54%	(1,180/1,348)
	Positive	50.00%	(2/4)	28.57%	(2/7)	12.46%	(168/1,348)
Tumor size	1-5mm	50.00%	(2/4)	30.00%	(3/10)	15.12%	(233/1,541)
	6-10mm	0.00%	(0/4)	10.00%	(1/10)	34.46%	(531/1,541)
	11-15mm	25.00%	(1/4)	20.00%	(2/10)	26.15%	(403/1,541)
	16-20mm	0.00%	(0/4)	20.00%	(2/10)	10.25%	(158/1,541)
Tumor size: > 20mm		25.00%	(1/4)	20.00%	(2/10)	14.02%	(216/1,541)
Tumor stage	0	0.00%	(0/1)	0.00%	(0/1)	15.34%	(148/965)
	I	0.00%	(0/1)	0.00%	(0/1)	44.04%	(425/965)
	II	0.00%	(0/1)	0.00%	(0/1)	8.91%	(86/965)
	III	0.00%	(0/1)	0.00%	(0/1)	2.80%	(27/965)

***Preliminary outcome data
Abnormal Interpretations and Cancers for Screening Mammography
Physician 1780697441: January-June 2017***

		1780697441		Facility 100853		All NMD facilities (N=359)	
Measure	Value	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)
	IV	0.00%	(0/1)	0.00%	(0/1)	0.52%	(5/965)
Assessment category	3	0.00%	(0/834)	0.06%	(2/3,236)	0.34%	(4,939/1,474,187)


Preliminary outcome data
Abnormal Interpretations and Cancers for Screening Mammography
Physician 1780766014: January-June 2017

		1780766014		Facility 100853		All NMD facilities (N=359)	
Measure	Value	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)
All exams			653		3,236		1,474,187
Recall rate		6.89%	(45/653)	9.46%	(306/3,236)	9.83%	(144,919/1,474,187)
PPV1		8.89%	(4/45)	6.86%	(21/306)	3.61%	(5,226/144,919)
Cancers and PPV2		40.00%	(2/5)	27.03%	(10/37)	18.94%	(4,071/21,492)
PPV3		33.33%	(1/3)	27.59%	(8/29)	27.33%	(3,526/12,900)
Biopsy recommended		0.77%	(5/653)	1.14%	(37/3,236)	1.46%	(21,492/1,474,187)
Biopsy performed		1.23%	(8/653)	1.64%	(53/3,236)	1.27%	(18,764/1,474,187)
Cancers and CDR per 1000		6.13	(4/653)	6.49	(21/3,236)	3.55	(5,226/1,474,187)
Invasive cancers and ICDR per 1000		4.59	(3/653)	4.33	(14/3,236)	2.70	(3,987/1,474,187)
DCIS		25.00%	(1/4)	33.33%	(7/21)	23.90%	(1,249/5,225)
Invasive cancer		75.00%	(3/4)	66.67%	(14/21)	76.31%	(3,987/5,225)
Minimal cancer		25.00%	(1/4)	68.75%	(11/16)	73.25%	(1,955/2,669)
Nodal status	Negative	No Data	(./.)	71.43%	(5/7)	87.54%	(1,180/1,348)
	Positive	No Data	(./.)	28.57%	(2/7)	12.46%	(168/1,348)
Tumor size	1-5mm	0.00%	(0/3)	30.00%	(3/10)	15.12%	(233/1,541)
	6-10mm	0.00%	(0/3)	10.00%	(1/10)	34.46%	(531/1,541)
	11-15mm	33.33%	(1/3)	20.00%	(2/10)	26.15%	(403/1,541)
	16-20mm	66.67%	(2/3)	20.00%	(2/10)	10.25%	(158/1,541)
Tumor size: > 20mm		0.00%	(0/3)	20.00%	(2/10)	14.02%	(216/1,541)
Tumor stage	0	No Data	(./.)	0.00%	(0/1)	15.34%	(148/965)
	I	No Data	(./.)	0.00%	(0/1)	44.04%	(425/965)
	II	No Data	(./.)	0.00%	(0/1)	8.91%	(86/965)
	III	No Data	(./.)	0.00%	(0/1)	2.80%	(27/965)


***Preliminary outcome data
Abnormal Interpretations and Cancers for Screening Mammography
Physician 1780766014: January-June 2017***

		1780766014		Facility 100853		All NMD facilities (N=359)	
Measure	Value	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)
	IV	No Data	(./.)	0.00%	(0/1)	0.52%	(5/965)
Assessment category	3	0.15%	(1/653)	0.06%	(2/3,236)	0.34%	(4,939/1,474,187)


***Preliminary outcome data
Abnormal Interpretations and Cancers for Screening Mammography
Recall Rate and PPV2
January-June 2017: Physician Comparisons***



***Preliminary outcome data
Abnormal Interpretations and Cancers for Screening Mammography
Cancer Detection Rate (CDR)
January-June 2017: Physician Comparisons***



***Preliminary outcome data
Abnormal Interpretations and Cancers for Screening Mammography
Biopsy Results
January-June 2017: Physician Comparisons***



Promote your participation in NRDR™!
Download your marketing toolkit today.

acr.org/NMDtoolkit

CONTACT US

1.800.227.5463, ext. 3535

nrdre@acr.org | nrdre.acr.org

